Der Spitzenverband der Gesetzlichen Krankenkassen (GKV) geht aktuell von einer Fachkräftelücke von 30.000 Vollzeitkräften in der Pflege aus. Wenn nicht entschlossen gegengesteuert werde, „wäre die Lage in zehn Jahren dramatisch“, sagte der GKV-Vizevorsitzende Gernot Kiefer den Zeitungen der Funke-Mediengruppe. Zentrales Problem sei, dass zu viele hochqualifizierte Pfleger zu früh aus dem Beruf gingen. Es sei […] GKV-Spitzenverband sieht Lücke von 30.000 Pflege-Vollzeitkräften

SPG601 is a once-a-day pill that works by restoring synaptic function to address core symptoms of Fragile X Syndrome SPG601 is a once-a-day pill that works by restoring synaptic function to address core symptoms of Fragile X Syndrome The post Spinogenix Announces U.S. FDA Approval of its Investigational New Drug Application for its Phase 2a… Spinogenix Announces U.S. FDA Approval of its Investigational New Drug Application for its Phase 2a Clinical Trial of SPG601 for Fragile X Syndrome

Portage Biotech Announces Plans to Expand its Evaluation of Strategic Alternatives -Adenosine clinical development paused Portage Biotech Announces Plans to Expand its Evaluation of Strategic Alternatives

ZURICH, Switzerland, April 15, 2024 (GLOBE NEWSWIRE) — BC Platforms (BCP), a global leader in real world data, healthcare data management, and analytics, today announces an exclusive collaboration with NTT Life Science Corporation, a company in the medical field of the NTT Group, to accelerate data-driven medicine. Last week, in Japan, an official opening ceremony of a joint Tokyo facility was held, housed within NTT Life Science, which will drive and develop the Japan Precision Medicine Platform™ (JPP). This marked the concrete beginning of the global partnership. The JPP has the power, for the first time in Japan to enable the usage of clinical data, ensuring the safe and efficient access, sharing and analysis of this data across the nation. JPP is a national medical data distribution platform to integrate, curate, and harmonize Japanese healthcare data enabled by BCP’s technology integrated… 

SØBORG, Dänemark, April 15, 2024 (GLOBE NEWSWIRE) — Cbio A/S – Pionier im Bereich T-Zell-Therapien der nächsten Generation für solide Tumore, gibt Finanzergebnisse für 2023 und aktuelle Unternehmensdaten bekannt. Cbio A/S, Entwickler von T-Zell-Therapien, stellt im Rahmen der Vorbereitungen zur klinischen Studie den Jahresbericht 2023 vor und kündigt mit einer gesicherten Finanzierung in Höhe von 40 Mio. DKK den Übergang zur klinischen Phase an

Soligenix announced today that the Office of Orphan Products Development of the United States (U.S.) Food and Drug Administration (FDA) has granted orphan drug designation to the active ingredient in MarVax™, the subunit protein vaccine of recombinantly expressed Marburg marburgvirus (MARV) glycoprotein, for „the prevention and post-exposure prophylaxis against MARV infection.“ MarVax™ is a subunit protein vaccine of recombinantly expressed Marburg marburgvirus (MARV) glycoprotein, developed in partnership with Dr. Axel Lehrer at the University of Hawai?i at M?noa. The vaccine includes a protein found on the surface of MARV, to engender an appropriate immune response without posing a risk of infection, as well as a novel adjuvant which stimulates both humoral and cell mediated immune responses, in combination with Generally Regarded as Safe (GRAS) excipients that enable lyophilization (i.e., freeze-drying) of the vaccine. The resulting product is manufactured as a… 

Premature deaths related to opioids doubled between 2019 and 2021 across Canada, with more than 1 in 4 deaths among young adults aged 20–39 years attributable to opioids, according to new research published in CMAJ (Canadian Medical Association Journal) Opioid-related deaths have continued to increase over the past decade across Canada, with 6222 deaths occurring in 2021. This trend worsened during the COVID-19 pandemic, although the scale and rapidity of increases varied across provinces and territories. These changes have been attributed primarily to the unregulated drug supply, which became increasingly volatile and unpredictable during the pandemic. JOURNALCanadian Medical Association Journal DOI10.1503/cmaj.231339

The Global Theranostics Market Size is to Grow from USD 1.9 Billion in 2023 to USD 3.3 Billion by 2033, at a Compound Annual Growth Rate (CAGR) of 5.68% during the projected period. Theranostics is a type of pharmaceutical treatment used in combination with diagnostics to maximize efficacy, safety, and expedite the discovery of new drugs. It is also known as integrated medicine, pharmacodiagnostics, companion diagnostics, and Dx/Rx partnership. It is the application of drugs in addition to diagnostic techniques. Theranostics is the process of combining medicinal treatment and diagnostics to expedite the creation of more affordable and effective medications. a quickly developing subject that the healthcare industry and regulatory organizations find intriguing. A number of factors are driving the global theranostics market, including the rising incidence of cancer globally and the resulting need for more specialized and potent therapies.… 

The Global Deepfake AI Market Size was Valued at USD 6.83 Billion in 2023 and the Worldwide Deepfake AI Market Size is Expected to Reach USD 119.34 Billion by 2033, according to a research report published by Spherical Insights & Consulting. Deepfake AI, or deep learning-based fake artificial intelligence, is the use of strong machine learning algorithms, particularly deep neural networks, to create or alter content that looks to be real but is actually artificial or fabricated. The term deepfake is derived from the combination of deep learning and fake. Deepfake AI technology is frequently used to make realistic-looking pictures, movies, or audio recordings using neural networks to mimic human behavior.

In einem Artikel in der Zeitschrift JAMA Pediatrics wurde festgestellt, dass der generative KI-Chatbot ChatGPT von OpenAI, den einige Gesundheitsorganisationen für begrenzte Anwendungsfälle getestet haben, bei der Diagnose pädiatrischer Krankheiten in 83 % der Fälle Fehler macht . Und beim Testen von OpenAIs GPT-4 als Diagnoseassistent stellten Ärzte am Beth Israel Deaconess Medical Center in Boston fest, dass das Modell in fast zwei von drei Fällen die falsche Diagnose als wichtigste Antwort einstufte. Die heutige generative KI hat auch mit medizinischen Verwaltungsaufgaben zu kämpfen, die fester Bestandteil der täglichen Arbeitsabläufe von Ärzten sind. Beim MedAlign-Benchmark zur Bewertung, wie gut generative KI Dinge wie das Zusammenfassen von Patientenakten und das Durchsuchen von Notizen leisten kann, scheiterte GPT-4 in 35 % der Fälle . OpenAI und viele andere Anbieter generativer KI warnen davor, sich bei medizinischer Beratung auf ihre Modelle zu verlassen…